Thomas Neumayer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Neumayer has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Eva Stifter
Department of Ophthalmology and Optometry, Medical University of Vienna, 1090 Vienna, Austria
2 shared publications - Lorenz Wassermann
Department of Ophthalmology and Optometry, Medical University of Vienna, 1090 Vienna, Austria
2 shared publications - Sandra Rezar-Dreindl
Department of Ophthalmology and Optometry, Medical University of Vienna, 1090 Vienna, Austria
2 shared publications - Angelika Berger
Comprehensive Center for Pediatrics, Department of Pediatrics and Adolescent Medicine, Division of Neonatology, Intensive Care and Neuropediatrics, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication - Johannes Engelmann
Department of Oral and Maxillofacial Surgery, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication - Mara Nike Blazon
Department of Ophthalmology and Optometry, Medical University of Vienna, Waehringer Gürtel 18-20, 1090 Vienna, Austria
1 shared publication
Latest Publications
- Open Access
- 8 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8726
Characteristics and Management of a Cohort of Patients with Asymmetric Thyroid Eye Disease and Unilateral Dysthyroid Optic Neuropathy Undergoing Unilateral Orbital Decompression Surgery
Background/Objectives: The aim was to describe the clinical characteristics and report the long-term outcomes of a cohort of patients with asymmetric thyroid eye disease (TED), including a subgroup with unilateral dysthyroid optic neuropathy (DON), treated with unilateral orbital decompression surgery alone or in combination with intravenous (IV) methylprednisolone. Methods: This retrospective study included 48 patients with asymmetric TED who all underwent orbital decompression with or without IV corticosteroid therapy between 2006 and 2020 at the Department of Ophthalmology and Optometry and Oral and Maxillofacial Surgery of the Medical University of Vienna, Austria. Results: The mean follow-up was 4.6 ± 2.6 years. Overall, 52% of the patients initially received IV corticosteroids followed by orbital decompression, and 73% underwent three-wall decompression. Mean visual acuity (VA) was 0.1 ± 0.5 logMAR at baseline and 0.1 ± 0.5 logMAR at final follow-up (p = 0.4). The mean reduction in proptosis was 4 ± 3 mm. Unilateral DON was diagnosed in 50% of the patients. In this subgroup, 67% were initially treated with IV corticosteroids and 79% underwent three-wall decompression. Mean reduction in proptosis was 5 mm. The final VA of the affected eye was <0.3 logMAR in 88% (21/24) of the patients with unilateral DON. Conclusions: Patients with asymmetric TED were predominantly treated with IV corticosteroids and received three-wall orbital decompression. Visual function could be maintained in a high number of cases with asymmetric TED and patients with unilateral DON.
- 8 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8726
Open AccessCharacteristics and Management of a Cohort of Patients with Asymmetric Thyroid Eye Disease and Unilateral Dysthyroid Optic Neuropathy Undergoing Unilateral Orbital Decompression Surgery
Background/Objectives: The aim was to describe the clinical characteristics and report the long-term outcomes of a cohort of patients with asymmetric thyroid eye disease (TED), including a subgroup with unilateral dysthyroid optic neuropathy (DON), treated with unilateral orbital decompression surgery alone or in combination with intravenous (IV) methylprednisolone. Methods: This retrospective study included 48 patients with asymmetric TED who all underwent orbital decompression with or without IV corticosteroid therapy between 2006 and 2020 at the Department of Ophthalmology and Optometry and Oral and Maxillofacial Surgery of the Medical University of Vienna, Austria. Results: The mean follow-up was 4.6 ± 2.6 years. Overall, 52% of the patients initially received IV corticosteroids followed by orbital decompression, and 73% underwent three-wall decompression. Mean visual acuity (VA) was 0.1 ± 0.5 logMAR at baseline and 0.1 ± 0.5 logMAR at final follow-up (p = 0.4). The mean reduction in proptosis was 4 ± 3 mm. Unilateral DON was diagnosed in 50% of the patients. In this subgroup, 67% were initially treated with IV corticosteroids and 79% underwent three-wall decompression. Mean reduction in proptosis was 5 mm. The final VA of the affected eye was <0.3 logMAR in 88% (21/24) of the patients with unilateral DON. Conclusions: Patients with asymmetric TED were predominantly treated with IV corticosteroids and received three-wall orbital decompression. Visual function could be maintained in a high number of cases with asymmetric TED and patients with unilateral DON.
- Open Access
- 17 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6926
Retinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in a Tertiary Care Center
Retinopathy of prematurity (ROP) remains a major cause of childhood blindness. Its pooled prevalence worldwide is 31.9%, and that of severe ROP is 7.5% among prematurely born babies. Investigating risk factors is essential for improving early detection and treatment outcomes. Purpose: To determine the frequency and stages of ROP cases and evaluate the treatment methods for premature infants at the Medical University of Vienna. Methods: In this retrospective study, 352 children who underwent ROP screening between 2018 and 2021 with a gestational age (GA) ≤ 32 weeks and/or a birth weight (BW) ≤ 1500 g were included. Results: ROP was found in 144 (40.9%) of the 352 screened premature infants, with 17 (4.8%) requiring treatment. Significant risk factors included GA and BW, while sex and pregnancy type were not significant. The mean GA was 27.7 ± 2.5 weeks, and the mean BW was 989.1 ± 359.7 g. Infants with ROP had a lower GA (25.9 ± 1.7 weeks) and BW (778.6 ± 262.4 g) than those without ROP (28.9 ± 2.2 weeks; 1134.9 ± 345.9 g). GA and BW were significantly lower in infants developing ROP (p < 0.001). Stage 2 ROP was the most common severity in 74 children (51.4%). Laser therapy was the most common first-line treatment, used in 11 infants (64.7%), followed by anti-VEGF therapy, used in 6 infants (35.3%). Children were treated within 1.0 ± 0.6 days on average. Of the 17 infants treated, 14 (82.4%) showed initial regression. Three infants (17.6%) required re-treatment: two with initial anti-VEGF therapy and one after laser therapy. Conclusions: The findings provide insights into ROP’s prevalence and treatment preferences at a university tertiary care center. GA and BW were confirmed to be significant predictors, aiding in early detection and informing treatment decisions. These insights will enable comparisons with similar studies and contribute to improved patient care.
- 17 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6926
Open AccessRetinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in a Tertiary Care Center
Retinopathy of prematurity (ROP) remains a major cause of childhood blindness. Its pooled prevalence worldwide is 31.9%, and that of severe ROP is 7.5% among prematurely born babies. Investigating risk factors is essential for improving early detection and treatment outcomes. Purpose: To determine the frequency and stages of ROP cases and evaluate the treatment methods for premature infants at the Medical University of Vienna. Methods: In this retrospective study, 352 children who underwent ROP screening between 2018 and 2021 with a gestational age (GA) ≤ 32 weeks and/or a birth weight (BW) ≤ 1500 g were included. Results: ROP was found in 144 (40.9%) of the 352 screened premature infants, with 17 (4.8%) requiring treatment. Significant risk factors included GA and BW, while sex and pregnancy type were not significant. The mean GA was 27.7 ± 2.5 weeks, and the mean BW was 989.1 ± 359.7 g. Infants with ROP had a lower GA (25.9 ± 1.7 weeks) and BW (778.6 ± 262.4 g) than those without ROP (28.9 ± 2.2 weeks; 1134.9 ± 345.9 g). GA and BW were significantly lower in infants developing ROP (p < 0.001). Stage 2 ROP was the most common severity in 74 children (51.4%). Laser therapy was the most common first-line treatment, used in 11 infants (64.7%), followed by anti-VEGF therapy, used in 6 infants (35.3%). Children were treated within 1.0 ± 0.6 days on average. Of the 17 infants treated, 14 (82.4%) showed initial regression. Three infants (17.6%) required re-treatment: two with initial anti-VEGF therapy and one after laser therapy. Conclusions: The findings provide insights into ROP’s prevalence and treatment preferences at a university tertiary care center. GA and BW were confirmed to be significant predictors, aiding in early detection and informing treatment decisions. These insights will enable comparisons with similar studies and contribute to improved patient care.